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Background: Compliance with annual ivermectin treatment is a major challenge in community-directed treatment
with ivermectin (CDTI) implementation. There are individuals who do not comply with the annual mass treatment,
which contributes to the continuity for disease transmission. Hence, ensuring high treatment coverage and sustained
compliance should be given due emphasis in the control of onchocerciasis. The aim of this study was to determine
CDTI compliance rate and predictors of compliance where the CDTI was in its 9th round in Kabo area, southwestern
Ethiopia.
Methods: Community-based cross-sectional study was conducted in Kabo area, three weeks after the 9th round of
annual ivermectin distribution. Systematic random sampling was used to select head of households and structured,
pre-tested questionnaire was used to interview the study participants. Data was analyzed using SPSS version 16.
Descriptive statistics was used to compute mean and standard deviation of continuous variables and frequency for
categorical variables, while bivariate and multivariate logistic regressions were used to assess the effects of independent
variables on the outcome variable. Variables which showed association in multivariate analysis were considered as final
predictors of compliance and strength of association was measured through adjusted odds ratio (AOR).
Results: A total of 308 respondents (age range 18-70, mean age ± SD, 32.21 ± 9.64) participated in the study. Of these,
249 (80.8%) reported that they took ivermectin during the 9th round annual treatment. Significantly higher rate of
treatment compliance was reported by participants age ≥35 years (AOR = 5.48, 95% CI; 1.97 - 15.23), participants who
stayed in the area for more than ten years (AOR = 3.86, 95% CI; 1.83- 8.11), participants who perceive that they are at
risk of contracting the disease(AOR = 7.05, 2.70- 18.43), participants who perceive community drug distributors (CDDs)
are doing their work well (AOR = 2.35 95% CI; 1.15- 4.83) and participants who know at least one CDD in their village
(AOR = 2.83, 95% CI; 1.26- 6.40).
Conclusion: The majority of the study participants in the present study area complied with ivermectin treatment.
Nevertheless, intervention packages should consider factors such as age, residence duration and community’s perception
of the disease to improve compliance and make drug distribution sustainable.
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Onchocerciasis is a debilitating vector-borne disease
caused by the parasite, Onchocerca volvulus; transmitted
by the bite of black-fly, Simulium damnosum [1]. The
disease is public health and socio-economic threat in
many African countries [2,3]. Worldwide there are more
than 120 million people at risk of contracting the dis-
ease, while 18 million people are already infected. More
than 99% of the disease burden is in Africa [4]. Oncho-
cerciasis affects the working age population, and it is the
second-leading infectious cause of blindness worldwide,
being responsible for about 500,000 blindness [5,6].
In Ethiopia, it is estimated that 3 million people are
already infected, whereas 7.3 million are at risk of infec-
tion. Nine regions surveyed for onchocerciasis were
found to be endemic and the endemic areas extend from
the northwest part to southwest part of the country
[3,7,8]. Onchocerciasis has been targeted for control and
eventually elimination, as a disease of public health and
socio-economic problems in Ethiopia along with 19
other African countries [1].
Annual mass treatment with an oral microfilaricidal
(ivermectin) is the main control strategy for onchocer-
ciasis in Ethiopia [9]. A community-directed treatment
with ivermectin (CDTI) strategy was adopted in line
with the African Program for Onchocerciasis Control
(APOC) since 1996. CDTI is a cost-effective strategy [6].
Several studies have shown that mass treatment with
ivermectin is safe and effective in reducing the transmis-
sion of the disease [2,10-14]. The annual mass treatment
must continue for about 15 years [15,16], while all eli-
gible members of the community should take the drug
in order to ensure an adequate reduction in the trans-
mission of the parasite and protection from further in-
fection [17]. Studies show that not all eligible members
of the community receive the annual treatment [18].
Hence, compliance with annual ivermectin treatment
has become a major challenge to put CDTI implementa-
tion on the ground.
Studies done elsewhere have shown that compliance
with ivermectin treatment can be influenced by factors
such as age and gender [16,19-21], beliefs about indivi-
dual susceptibility to onchocerciasis [16,22], programme
organization, perceived social influence and support, per-
ceived benefits of ivermectin treatment [22], characte-
ristics of the client, perceived performance of CDDs/
providers [16,22] and methods of dose determination [16].
CDTI is currently on-going in Ethiopia. However, there is
limited information regarding treatment compliance rate
and factors affecting treatment compliance. Therefore, the
aim of this study was to determine the rate of compliance
with CDTI and identify factors influencing compliance
with CDTI in Kabo area, which would contribute to the
success of the on-going program.Methods
Study area and population
Community-based cross-sectional study was conducted
in Kabo area, Gambella Regional State, southwestern
Ethiopia, between November and December 2012. The
study area is located about 667 kilometers south west of
Addis Ababa and 340 kilometers from Gambella Town.
The major ethnic composition of the area include Amhara,
Oromia, Tigre, Kafficho, Kambata, Shakacho, Mezhenger
and some others from southern Ethiopia. Most of the in-
habitants are engaged in mixed farming like coffee planta-
tion, maize cultivation and rearing livestock. Based on the
2007 Ethiopian National Population and Housing Census,
the population of the area is projected to be about 46,583,
with 23,429 males and 23,154 females [23].
Community-based treatment with ivermectin (Mectizan®)
for the control of onchocerciasis was initiated in the area
in 2004 by World Health Organization (WHO)/APOC in
partnership with Ethiopian Federal Ministry of Health
(FMOH), The Carter Centre, the local administration and
the communities [23]. Since then, ivermectin has been
annually distributed to all eligible members of the com-
munity in the villages through CDDs [23], using the height
and physical appearance dosing method [24]. According
to the information obtained from Gambella Regional
Health Bureau (GRHB), in 2011 the annual treatment
coverage of ivermectin in the area was around 76% [23].
Sample size estimation and data collection
To determine the number of participants to be included
in the study, single population proportion formula was
used with the assumption that: the proportion of iver-
mectin treated individuals (treatment compliers) in the
community was 75.8% [23], confidence level 95% and
degree of precision 5%. To compensate for the non-
respondents, 10% was considered and thus, the final
sample size was estimated to be 308.
The study area was stratified into four manageable
villages based on their proximity. Then, the sample size
was distributed proportionally to each village based on
their population size. Systematic random sampling tech-
nique was used to recruit the households for this study,
and heads of households (i.e. husband or wife or any
representative), aged 18 years and older, and who stayed
in the area for more than one year, apparently healthy,
and volunteered to participate were included in this
study. Pregnant and lactating women having infants
younger than one month of age (during the data collec-
tion period) and individuals who were seriously sick
were excluded from the study since they had already
been excluded from the mass treatment.
A structured, pre-tested questionnaire was used for
data collection. The questionnaire was adopted from
similar studies conducted previously [16,22]. It has three
Table 1 Socio-demographic characteristics of 308 study
participants recruited from the community, Kabo area,
southwestern Ethiopia, 2012
Variables Category Freq (%)
Sex Male 183 (59.4)
Female 125 (40.6)
Age group ≤35 213 (69.2)
>35 95 (30.8)











Marital status Married 231 (75.0)
Single 77 (25.0)
Educational status Illiterate 144 (46.8)
Literate 164 (53.2)
Length of stay <10 Years 74 (24.0)
≥10 Years 234 (76.0)
Occupation Farmer 221 (71.8)
Others 87 (28.2)
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factors (such as knowledge, belief and attitude/perception
towards the treatment, the disease, and CDDs) and service
related factors. The service related factors here refer to
activities related to service provision such as timing of ser-
vice provision (week end, working days, holidays), decision
maker of ivermectin distribution (Woreda/District Office,
CDDs, Community leaders, HEWs), places of service
provision (home to home, fixed village centers and others)
and sources of information about the service (family, local
leaders, health workers, health extension workers, CDDs,
friends, religious leaders, radio and others). The question-
naire was prepared in English and then, translated into
Amharic and back to English to check for its consistency.
The survey was conducted three weeks after the 9th
round of annual ivermectin distribution in the area. The
participants were interviewed in local languages by trained
data collectors who were selected from the area and the
interview made by house-to-house visit.
Data entry and analysis
After the completion of data collection, cleaning, editing
and coding was done. Then the data were entered using
EpiData software, V.3.1 and analyzed using SPSS version
16.0. Descriptive statistics was used to compute mean and
standard deviation of continuous variables and frequency
for categorical variables. Bivariate and multivariate logistic
regressions were used to assess the effects of independent
variables on the outcome variable, while simultaneously
controlling for other potential confounding factors.
To identify independent predictors of compliance with
ivermectin treatment, backward multivariate logistic re-
gression method was used. Variables which showed asso-
ciation in multivariate analysis at 5% level of significance
were considered as final predictors of compliance with
ivermectin treatment. The strength of association between
different exposure variables and the outcome variable was
measured through adjusted odds ratio.
Ethical considerations
The study was carried out after obtaining ethical ap-
proval from the Institutional Review Board (IRB) of
Aklilu Lemma Institute of Pathobiology, Addis Ababa
University. Then, permission was obtained from GRHB,
Zonal Health Departments & District Health Offices. Be-
fore the interview commenced, informed verbal consent
was obtained from all study participants after explaining
the objective of the study to the participants.
Results
Socio-demographic characteristics of respondents
A total of 308 participants (age range 18-70 years, mean
age 32.21 ± 9.64 years) were interviewed yielding a response
rate of 100%. The mean length of stay of respondents inthe study area was 17.13 ± 8.64 years. Table 1 shows the
socio-demographic characteristics of the participants.
CDTI compliance rate
About 80.8% (249/308) of the respondents took the
treatment. The remaining 19.2% (36 males and 23
females) eligible individuals did not comply with the
annual treatment. The mean age (±SD) of respondents
who comply with the treatment and those that did not
comply with the treatment was 32.92 (±9.35) and 29.20
(±1.03), respectively. The most frequently mentioned
reasons for missing the treatment were: absence (due to
farming) during the campaign day (37.3%), CDDs did
not come to their house to provide them with the treat-
ment (20.4%), do not trust the importance of the treat-
ment (13.6%) and other reasons such as fear of side
effects and shortage of drug (11.8%) (Table 2).
CDTI compliance rate versus socio-demographic factors
As shown in Table 3, the magnitude of compliance
with ivermectin treatment did not show a significant
Table 2 CDTI compliance rate of the study participants in
Kabo area, southwestern Ethiopia, 2012
Variables (N = 308) Category Freq (%)
Did you receive ivermectin in the
recent campaign (this year)?
Yes 249 (80.8)
No 59 (19.2)
If no what was the reason?
(n = 59)
Absence (farming) 22 (37.3)
CDDs not coming to
their house
12 (20.4)
Not being informed 10 (16.9)
Believing free things
are useless for health
8 (13.6)




From where do you collect the
tablet? (n = 249)
CDDs come to my
house
213 (85.5)
From village center 35 (14.1)
From CDDs house 1 (0.4 )
Table 3 CDTI compliance rate versus socio-demographic facto
southwestern Ethiopia, 2012
Variables (N = 308) Category (no.) C
Y
Sex Male (183) 1
Female (125) 1
Age group ≤35 Years (213) 1
>35 Years (95) 8
Ethnicity Indigenous (13) 7
Others (295) 2




Marital status Married (231) 1
Single (77) 6
Educational status Illiterate (144) 1
Literate (164) 1
Family size 1-4 (173) 1
5-8 (113) 9
9+ (22) 1
Length of stay <10 Years (74) 4
≥10 Years (234) 2
Occupation Farmer (221) 1
Others (87) 7
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males) and marital status (81.0% for married and 80.5%
for single respondents) categories (P > 0.05). Relatively,
higher rate of treatment compliance was reported among
respondents with age greater than 35 years (93.7%)
compared to those with age 35 years and less (75.1%)
(P < 0.05). Statistically significant difference was also ob-
served with respect to length of stay. Compliance to treat-
ment was higher for those who stayed in the area for ten
years and more (87.2%) compared to those who stayed for
less than ten years (60.8%) (P < 0.05). Educational status
and ethnicity also showed a significant association with
treatment compliance. Higher treatment compliance rate
was reported by literate (86.0%) compared to illiterate
(75.0%). Regarding family size, the magnitude of com-
pliance to treatment seems higher for those with family
size 1-4 (82.1%) compared to those of households ha-
ving nine and more family members (68.2%), but it did
not show a statistically significant difference (p > 0.05).
There was no significant difference observed in compli-
ance rate with regard to the type of occupation, 79.6%
for farmers compared to 83.9% for those of respondents
engaged in other occupations (p > 0.05).rs among the study participants in Kabo area,
ompliance to Ivermectin P-value
es (%) No (%)
47 (80.3) 36 (19.7) 0.78
02 (81.6) 23 (18.4)
60 (75.1) 53 (24.9) 0.00
9 (93.7) 6 (6.3)
(53.8) 6 (46.2) 0.01
42 (82.0) 53 (18.0)
22 (83.0) 25 (17.0) 0.20
3 (84.0) 12 (16.0)
2 (72.2) 20 (27.8)
2 (85.7) 2 (14.3)
87 (81.0) 44 (19.0) 0.93
2 (80.5) 15 (19.5)
08 (75.0) 36 (25.0) 0.02
41 (86) 23 (14)
42 (82.1) 31 (17.9) 0.29
2 (81.4) 21 (18.6)
5 (68.2) 7 (31.8)
5 (60.8) 29 (39.2) 0.00
04 (87.2) 30 (12.8)
76 (79.6) 45 (20.4) 0.39
3 (83.9) 14 (18.1)
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factors
Respondents were asked about their awareness of
onchocerciasis, the responsible vector (insect) for the
transmission of the disease, way of transmission and the
sign and symptoms of the disease. The rate of compli-
ance to treatment was higher (83.0%) among respon-
dents who knew/heard about onchocerciasis compared
to those who did not know about the disease (35.7%)
(P < 0.05). Relatively higher rate of treatment com-
pliance was reported by respondents who know the
responsible vector, means of transmission and signs/
symptoms of onchocerciasis (84.6%, 79.2% and 82.8%
respectively) compared to their counter parts, but it was
not statistically significant. Furthermore, the respondents
were asked about the responsible body for distributing
the tablet. Those who said CDDs, were significantly
over represented (89.5%) under treatment compliance
compared to those who said health extension workers
(55.6%), health professionals (50.0%), and others (46.7%)
(p < 0.05). On top of this, those respondents who know
at least one CDD in their village had significantly higher
rate of treatment compliance (89.2%) compared to
those who do not know any CDD in their village (43.9)
(p < 0.05) (Table 4).
The magnitude of compliance to treatment was signifi-
cantly higher for respondents who perceive onchocercia-
sis as a serious disease (91.2%) and common in their
village (92.6%) compared to those who perceive oncho-
cerciasis as not serious (30.3%) and not common in their
village (46.8%) (p < 0.05). Similarly, those who perceive
that they are at risk of contracting the disease had
significantly higher treatment compliance rate (97.4%)
compared to those who perceive themselves not at risk
of getting onchocerciasis (27.6%) (p < 0.05). In addition,
respondents who perceived CDDs are performing their
work well had significantly higher compliance rate (89.1%)
compared to those who deem CDDs are poor in perform-
ance (12.1%) (p < 0.05). Furthermore, respondents who
perceived that CDTI as very important (87.9%) and the
program can control onchocerciasis (89.1%) had signifi-
cantly higher compliance rate compared to those who
look at CDTI as an obligation (7.4%) and those who
believe the program can’t control onchocerciasis (33.3%)
(p < 0.05) (Table 4).
None of the service-related factors (timing of service
provision, decision maker of service periods, places of
service provision and sources of information about the
service) was associated with compliance to ivermectin
treatment.
Independent predictors of compliance with CDTI
Crude analysis of socio-demographic variables (Table 3)
showed that age, educational status, ethnicity and lengthof stay in the study area were significantly associated
with compliance to ivermectin treatment (p < 0.05). On
the other hand; sex, marital status, religion, occupation,
family size and monthly income did not show statisti-
cally significant association. While among the behavioral
factors (Table 4); awareness of onchocerciasis, percep-
tion towards onchocerciasis, perceived performance of
CDDs, perception towards the CDTI and the program,
knowing a person stopped treatment in their village,
awareness regarding a person (professional) responsible
for distributing ivermectin and knowing at least one
CDD in their village had shown significant association
with compliance to ivermectin treatment. Knowledge on
the responsible vector for the transmission, mode of
transmission and sign and symptoms, previous family
history of onchocerciasis, awareness on how CDDs
recruited, awareness of other useful effects of ivermectin,
methods of ivermectin dose determination, existence of
problem with drug distribution, and participation in
community meeting regarding CDTI from the behavioral
factors did not show statistically significant association
with compliance to CDTI in the bivariate analysis.
All variables that were significant in bivariate ana-
lysis were used in the multivariate logistic regression
analysis to identify independent predictors of com-
pliance to CDTI. Consequently, five variables were
found to have statistically significant association with
compliance to ivermectin treatment after adjusting for
other variables. Age, length of stay, risk perception to
onchocerciasis, perception towards the performance of
CDDs and familiarity with at least one CDD in their
village independently showed significant association
(Table 5).
Respondents with age greater than 35 years old were
5.48 times more likely to comply with CDTI compared
to those whose age was less than or equal to 35 years
(adjusted odds ratio = 5.48; 95% CI: 1.97 - 15.23). Simi-
larly, individuals who stayed in the study area for more
than or equal to ten years were 3.86 times more likely to
comply with the treatment compared to those who
stayed in the area for less than ten years (adjusted odds
ratio = 3.86; 95% CI: 1.83 - 8.11). The respondents who
perceived themselves to be at risk of onchocerciasis in-
fection were 7.05 times more likely to comply with the
treatment compared to those who did not (adjusted odds
ratio = 7.05; 95% CI: 2.70 - 18.43). In addition, respon-
dents who perceived that CDDs are doing their work
well were 2.35 times more likely to comply with CDTI
compared to their counter parts (adjusted odds ratio =
2.35, 95% CI: 1.15, 4.83). Moreover, respondents who
know at least one CDD in their village were 2.83 times
more likely to comply with CDTI compared to those
who did not know any CDD in their village (adjusted
odds ratio = 2.83; 95% CI: 1.26 - 6.40) (Table 5).
Table 4 Compliance rate versus behavioral factors among the study participants in Kabo area, southwestern
Ethiopia, 2012
Variables (N = 308) Category (no.) Compliance with Ivermectin P-value
Yes (%) No (%)
Know (heard about) the disease onchocerciasis Yes (294) 244 (83.0) 50 (17.0) 0.00
No (14) 5 (35.7) 9 (64.3)
Know the vector (Black fly) for transmission Yes (26) 22 (84.6) 4 (15.4) 0.61
No (282) 227 (80.5) 55 (19.5)
Know mode of transmission (Black fly bite) Yes (24) 19 (79.2) 5 (20.8) 0.83
No (284) 230 (81.0) 54 (19.0)
Know sing and symptoms (at least one) Yes (227) 188 (82.8) 39 (17.2) 0.82
No (81) 61 (75.3) 20 (24.7)
The responsible body for distributing the drug CDDs (237) 212 (89.5) 25 (10.5) 0.00
HEWs (36) 20 (55.6) 16 (44.4)
Health professionals (20) 10 (50.0) 10 (50.0)
Others (15) 7 (46.7) 8 (53.3)
Know any CDD in their village Yes (251) 224 (89.2) 27 (10.8) 0.01
No (57) 25 (43.9) 32 (56.1)
Know how CDDs recruited Yes (121) 101 (83.5) 20 (16.5) 0.35
No (168) 148 (79.1) 20 (20.9)
Attend village meeting on CDTI at least once Yes (174) 144 (82.8) 30 (17.2) 0.33
No (134) 105 (78.4) 29 (21.6)
Onchocerciasis a serious disease Yes (260) 237(91.2) 23(8.8) 0.00
No (33) 10(30.3) 23(69.7)
Onchocerciasis common in their village Yes (243) 225 (92.6) 18(7.4) 0.00
No (47) 22 (46.8) 25 (53.2)
Risk perception to onchocerciasis Yes at risk (252) 222(88.1) 30(11.9) 0.00
Not at risk (34) 16 (27.6) 18 (72.4)
Perceived performance of CDDs Good (217) 191(88.0) 26 (12.0) 0.00
Poor (91) 58 (63.7) 33 (36.3)
Perceived importance of CDTI As very important (281) 246(81.7) 55 (18.3) 0.01
As obligation (27) 3 (42.9) 4 (57.1)
Perception towards the program (can control onchocerciasis) Yes (274) 244(89.1) 30(10.9) 0.00
No (3) 1(33.3) 2(66.7)
Know a person who stopped treatment Yes (16) 9(56.2) 7 (43.8) 0.01
No (292) 240 (82.2) 52 (17.8)
Perceived reason of stopping the treatment Sever effect of the drug 2 (40.0) 3 (60.0) 0.53
Lack of good case mgt. 5 (71.4) 2 (28.6)
Others 2 (50.0) 2 (50.0)
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The results of this study indicated that 80.8% of the re-
spondents took ivermectin during the 9th round of the
annual ivermectin distribution. Although the treatment
coverage seems good, there is a need to attain and main-
tain a high coverage of CDTI; at least 90%, for elimin-
ation of onchocerciasis as a public health problem
[17,25]. In this study, almost one fifth (19.2%) of eligiblerespondents in the community were non-compliers to
CDTI. This implies that members of the community
who do not take the treatment may serve as a reservoir
for continued transmission of onchocerciasis in the area.
The major reasons for not taking the annual treatment
include: being in the field (farming) during the campaign
day, homes not being visited by CDDs, not being
informed about the campaign day, do not trust the
Table 5 Independent predictors of CDTI in Kabo area, southwestern Ethiopia, 2012
Variables Compliance with Iv. Crude OR (95% CI) Adjusted OR (95% CI)
Yes No
Age group ≤35 Years 160 53 Reference Reference
>35 Years 89 6 4.91 (2.03, 11.88) 5.48 (1.97, 15.23)
Length of stay <10 Years 45 29 Reference Reference
≥10 Years 204 30 4.38 (2.40, 8.02 ) 3.86 (1.83, 8.11)
Perceived risk Yes at risk 222 30 8.33 (3.84, 18.05) 7.05 (2.70, 18.43)
Not at risk 16 18 Reference Reference
Perceived performance of CDDs Good 191 26 4.18 (2.31, 7.56) 2.35 (1.15, 4.83)
Poor 58 33 Reference Reference
Familiarity with CDDs (at least one) Yes 214 37 3.64 (1.92, 6.88) 2.83 (1.26, 6.40)
No 35 22 Reference Reference
Endale et al. Parasites & Vectors  (2015) 8:99 Page 7 of 8treatment, and other reasoning’s such as fear of side
effects. A study conducted in Uganda showed that
among those individuals eligible for treatment, 17.4%
were reported as non-compliers in the tenth round of
ivermectin distribution [22], although their study did
not indicate the reasons. Another study conducted in
Nigeria reported that absenteeism during the campaign
day was the major reason for missing the treatment [26].
The need to understand factors contributing to com-
pliance to CDTI is paramount for improving the efforts
in the prevention and control of onchocerciasis as an
economic and public health problem. Findings of this
study showed that age over 35 years, length of stay, per-
ception about risk of contracting onchocerciasis, per-
ception of the performance of CDDs and familiarity
with CDDs in their villages were the factors found to be
independent predictors of compliance with ivermectin
treatment. Older age groups (age >35 years) had a posi-
tive association with CDTI compliance and were almost
five and half times more likely to comply with the treat-
ment compared to younger ones. The finding is consist-
ent with a study conducted in Nigeria and Cameroon
[19,27]. The reason may be attributed to the fact that
younger individuals are relatively highly mobile and
likely to travel outside the village for work and other op-
portunities or they could be reluctant and miss the an-
nual treatment. Moreover, a shorter period of ivermectin
distribution that lasts for just a few days possibly in-
creases the number of non-compliers. Respondents who
stayed in the study area for ten years and more were
more likely to comply with the treatment compared to
those who stay in the study area less than ten years. This
might be due to the fact that the more a person stays in
the endemic area, the more he/she acquires relevant
information on the benefits of the treatment from the
existing intervention package in the area.
The strongest factor associated with compliance to
CDTI in this study was perceived personal risk ofonchocerciasis. Individuals who perceive that they are at
risk of getting the infection were nearly seven times more
likely to comply with CDTI compared to those who con-
sider themselves as free from risk of the infection. Other
studies also showed that when people believe that per-
sonal susceptibility to onchocerciasis is high then, adhe-
rence to the treatment is also high [16,18,22,28].On top of
this, the finding also demonstrated a pivotal role of CDDs
in the success of CDTI. Perceived good performance of
CDDs and knowing at least one CDD was associated with
increased compliance. Thus, respondents who perceive
CDDs are doing their work well were more likely to com-
ply with the treatment and those who know at least one
CDD in their village were likely to comply with CDTI
compared to their counter parts. This finding is in
congruent with the studies conducted in southwestern
Ethiopia, Nigeria and Uganda [16,19,22]. The study con-
ducted in southwestern Ethiopia (Bebeka coffee planta-
tion) revealed insufficient knowledge on the side of CDDs
resulted in hampered acceptability of CDDs performance
by the community [16]. It is important that CDDs are able
to carry out their tasks and need regular training [29].
One of the limitations of this study was that we used a
cross-sectional study design, which is a snapshot of a
single point in time and misses the seasonal trends of
CDTI compliance rate in the study area. Since the docu-
mentation and registration system of CDTI implemen-
tation was weak in the area, to avoid recall bias we
conducted a cross-sectional study just three weeks after
the annual ivermectin distribution. The other limitation
was that a relatively higher degree of accuracy (5% de-
gree of precision) was used which limits our sample size
to 308.
Conclusion
In conclusion, the annual treatment coverage of iver-
mectin in the study area seems good, but this does not
mean that all eligible individuals have been complying
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that do not comply with the annual treatment particularly
younger individuals, recent comers and reluctant. Hence,
a special emphasis needs to be given for these segments of
population to increase awareness about perceived personal
risk of onchocerciasis and so to address the issue of non-
compliance. Moreover CDDs need to be continuously
motivated and supported to perform their work well and
also they should have to develop a rapport with the com-
munity members. On top of this, there is a need for fur-
ther operational research for achieving and sustaining
high level of coverage.
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